Quick Answer
Vivos Therapeutics, Inc. reported Operating Income of -$11.17 million for fiscal year 2024.
Vivos Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$11.17M | +35.4% |
| 2023 | -$17.30M | +30.9% |
| 2022 | -$25.03M | -22.8% |
| 2021 | -$20.38M | -69.3% |
| 2020 | -$12.04M | -13.8% |
| 2019 | -$10.58M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.73M | -79.0% | +2.7% |
| June 30, 2025 | -$4.87M | -151.3% | -24.2% |
| March 31, 2025 | -$3.92M | -3.5% | -48.1% |
| September 30, 2024 | -$2.65M | +27.3% | -36.6% |
| June 30, 2024 | -$1.94M | +57.1% | +48.9% |
| March 31, 2024 | -$3.79M | +24.4% | -4.0% |
| September 30, 2023 | -$3.64M | +32.7% | +19.4% |
| June 30, 2023 | -$4.52M | +35.1% | +9.8% |
- Vivos Therapeutics, Inc. showed an increase of +35.4% in Operating Income compared to the prior fiscal year.
- Over the 2019–2024 period, Vivos Therapeutics, Inc.’s operating income has declined by 5.6% (from -$10.58 million to -$11.17 million).
- The most recent figure is from Vivos Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: